Futurechem Co., Ltd

Industry-university Cooperation Foundation Sogang University

Piramal Imaging Sa

Life Molecular Imaging Sa

Byoung Se Lee

Dae Yoon Chi

So Young Chu

Hyeon Jin Jeong

Yong Jin Lee

Min Hwan Kim

Kyo Chul Lee

Woon Jung Jung

Heribert Schmitt-Willich

Mi Hyun Kim

Jae Seung Kim

Mathias Berndt

Matthias Friebe

Michael Harre

Sang Moo Lim

Seung Jun Oh

Yu Jin Bae

Jin-sook Ryu

Ji Ae Park

Dae Hyuk Moon

Christina Hultsch

Heejun Kim

Sang Don Park

Filip Novak

Hyeon Seok Kim

Ran Ji Yoo

Youjung Jung

Uthaiwan Sirion

Jae Hak Lee

Yoo Jin Lim

Chi Dae Yoon

The present invention relates to a pharmaceutical composition for diagnosing and treating prostate cancer, capable of targeting PSMA, and a compound provided by one aspect of the present invention has a glutamine-urea-lysine compound to which a radioactive metal-coupled chelator is structurally coupled and to which an aryl group that can additionally bind to PSMA protein is coupled. Coupling between the glutamine-urea-lysine compound and the chelator includes a polar spacer so as to serve the role of reducing in vivo nonspecific coupling and exhibit an effect of being rapidly removed from vital organs, but not from prostate cancer. These characteristics lower the radiation exposure, which is caused by a therapeutic radioisotope-coupled compound, to normal tissue and organs, and thus reduce side effects. In addition, a compound that contains a phenyl group having a coupling force with albumin has an increased residence time in the blood, thereby becoming more accumulated in prostate cancer.

PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer

The present invention relates to a process for producing an organofluoro compound including [F]fluorine, and by using a solvent represented by Formula 1 in nucleophilic fluorination reaction, an organofluoro compound may be prepared at a high yield. In addition, since the solvent has very excellent solubility for a precursor compound, the solvent is suitable for the automated synthesis ofF-labeled radiopharmaceuticals.

Process for producing fluorinated compounds using alcohol solvent having unsaturated hydrocarbon

The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when used in positron emission tomography (PET).

18F-labelled compound for prostate cancer diagnosis, and use thereof

The present invention relates to a method for synthesizing a radiopharmaceutical using a cartridge, which makes it possible to carry out several steps of reaction required for synthesizing a radiopharmaceutical in the cartridge filled with a polymer. A method for synthesizing a radiopharmaceutical according to the present invention enables each step's reaction to be carried out with the solution confined in the cartridge so as not to flow out, thus being simplified compared to the conventional methods for synthesizing radiopharmaceuticals, and expediting the synthesis thereof.

Method for synthesizing radiopharmaceuticals using a cartridge

This invention relates to novel precursors suitable forF radiolabeling of glutamate derivatives, methods for preparing such compounds and its intermediates, compositions comprising such compounds, kits comprising such compounds or compositions and methods forF radiolabeling of glutamate derivatives wherein the obtainedF radiolabeled glutamate derivatives are suitable for diagnostic imaging by Positron Emission Tomography (PET) of proliferative diseases e.g. tumor in mammals.

Precursors of glutamate derivatives

2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for &#x3b2;-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R-R, V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight &#x3b2;-amyloid peptide binding compound, generation of malignant high-molecular weight &#x3b2;-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.

2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient

Growing community of inventors

Seoul, South Korea

Byoung Se Lee